Trial Profile
Single Dose, Open Label, Uncontrolled, Safety Trial of Intravenous Administration of Idarucizumab to Paediatric Patients Enrolled From Ongoing Phase IIb/III Clinical Trials With Dabigatran Etexilate for the Treatment and Secondary Prevention of Venous Thromboembolism.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Jan 2022
Price :
$35
*
At a glance
- Drugs Idarucizumab (Primary)
- Indications Venous thromboembolism
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim; Boehringer Ingelheim Pharma KG
- 16 Apr 2020 Results published in the European Clinical Trials Database Trial Registry
- 14 Apr 2020 Results published in the ClinicalTrials.gov Trial Registry
- 01 Feb 2020 This trial is discontinued in Spain, according to European Clinical Trials Database record.